DeepMind Spinout Isomorphic Labs Raises $2.1 Billion to Design Drugs With AI

Alphabet Inc.’s Isomorphic Labs raised $2.1 billion in its second round of outside capital, with new support from sovereign wealth funds, as it seeks to make artificial intelligence-designed drugs a reality.

Venture firm Thrive Capital led the round, which also included Alphabet, Abu Dhabi’s MGX, Singapore’s Temasek and the UK’s Sovereign AI fund, Isomorphic Labs said in a statement Tuesday. Bloomberg News previously reported on the financing plans.